Tinostamustine Conditioning and Autologous Stem Cell
Status:
Terminated
Trial end date:
2019-04-17
Target enrollment:
Participant gender:
Summary
Phase 1
The primary objectives of Phase 1 of this study are to:
- Establish the safety, toxicity, and maximum tolerated dose (MTD) of the tinostamustine
conditioning regimen.
- Identify the recommended Phase 2 dose (RP2D) of tinostamustine for use in the Phase 2
portion of the study.
The secondary objective of Phase 1 of this study is to:
- Investigate the pharmacokinetics (PK) of tinostamustine.